Q&A: Poolbeg Pharma on target for $1bn cancer opportunity
Episode 1771, Jan 17, 07:49 AM
(Watch the video interview HERE)
Vox Markets talks to Poolbeg Pharma #POLB CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy.
0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS
1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting
3:12 How an Independent Advisory Board is supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS.
5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg
Vox Markets talks to Poolbeg Pharma #POLB CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy.
0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS
1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting
3:12 How an Independent Advisory Board is supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS.
5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg